Proteomic profiling of growth hormone-responsive proteins in human peripheral blood leukocytes.

What Was Tested

The paper reports a study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over), published as a randomized controlled trial.

Their objective was to explore a novel approach for the detection of GH-responsive proteins in human leukocytes by proteomic analysis using SELDI-TOF MS.

Why It Was Studied

GH is a known modulator of the immune system, but the effect of exogenous GH administration on white blood cell proteins has not been investigated.

Surface-enhanced laser desorption/ionization time-of-flight mass spectrometry (SELDI-TOF MS) is a powerful platform for the study of GH effects on immune system proteins.

Who Took Part

The study group was 30 subjects.

PubMed tags the participants as both men and women.

The researchers conducted a randomized double-blind, placebo-controlled GH administration study of 8 wk treatment followed by 6 wk washout.

Pre- and posttreatment samples from 30 subjects were used for biomarker discovery.

How the Study Was Run

In design terms this was a randomized, double-blind and placebo-controlled study.

Because people in this Exogenous HGH, sermorelin & older GHRPs (why they're passed over) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Blinding on both sides kept the subjects and researchers unaware of who received Exogenous HGH, sermorelin & older GHRPs (why they're passed over).

The comparison arm used a placebo, so changes seen with Exogenous HGH, sermorelin & older GHRPs (why they're passed over) could be set against what happens without it.

The study was performed at a clinical research facility.

What Was Measured

PubMed files the paper under topics including Blood Proteins, Human Growth Hormone, Leukocytes, Proteomics, S100 Proteins and Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in 30 subjects.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The abstract goes on to report its results in about 5 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2009 (The Journal of clinical endocrinology and metabolism), a journal based in United States.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.